AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11975149 — intervention group
Group type: COMPARATOR
Intervention: Mixed-use learning of transformations
Number of subjects: 0
Study 9596181 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar stimulation modes
Number of subjects: 5
Study 9596181 — intervention group
Group type: COMPARATOR
Intervention: Bipolar stimulation mode
Number of subjects: 5
Study 7816379 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-MAG3 renogram deconvolution in healthy kidneys
Number of subjects: 78
Study 7816379 — intervention group
Group type: COMPARATOR
Intervention: 99Tcm-MAG3 renogram deconvolution in normal functioning kidney grafts
Number of subjects: 78
Study 3399331 — intervention group
Group type: COMPARATOR
Intervention: 5% bandwidth group (BW5)
Number of subjects: 0
Study 3399331 — intervention group
Group type: COMPARATOR
Intervention: 10% bandwidth group (BW10)
Number of subjects: 0
Study 3399331 — intervention group
Group type: COMPARATOR
Intervention: Control group (KR)
Number of subjects: 0
Study 31925185 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted insulin (per pmol/L higher insulin)
Number of subjects: 392010
Study 28449232 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mg GSK2881078 (in women)
Number of subjects: 99
Study 28449232 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg, 0.2 mg, 0.08 mg, 0.24 mg, 0.48 mg, 0.75 mg GSK2881078 (in men)
Number of subjects: 99
Study 28449232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in women)
Number of subjects: 99
Study 28449232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in men)
Number of subjects: 99
Study 26381232 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 1100
Study 26381232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 23398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1, 60 CGE/20 fractions/5 weeks
Number of subjects: 82
Study 23398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2, 54 CGE/15 fractions/5 weeks
Number of subjects: 82
Study 23398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 3, 47 CGE/10 fractions/5 weeks
Number of subjects: 82
Study 23398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 4, 35 CGE/5 fractions/2.5 weeks
Number of subjects: 82
Study 23398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 5, 35 CGE/5 fractions/5 weeks
Number of subjects: 82
Study 23398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 82
Study 21723443 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women with PCOS
Number of subjects: 242
Study 20017932 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (Quinapril) or Statins (Atorvastatin) or combination therapy
Number of subjects: 500
Study 20017932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 16761149 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transfusion drain (Bellovac)
Number of subjects: 104
Study 16761149 — intervention group
Group type: COMPARATOR
Intervention: Standard suction drain (Redivac)
Number of subjects: 104
Study 15152893 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (CysLTs type‐1 receptor antagonist)
Number of subjects: 11
Study 15152893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15152893 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 11
Study 11700185 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular formulation of the insect growth regulator pyriproxyfen at a target dose of 0.01 mg a.i./litre
Number of subjects: 8
Study 11700185 — intervention group
Group type: COMPARATOR
Intervention: Control villages (not treated with pyriproxyfen)
Number of subjects: 8
Study 11700185 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular formulation of the insect growth regulator pyriproxyfen
Number of subjects: 8
Study 9383759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant (Delton)
Number of subjects: 314
Study 9383759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish (Duraphat)
Number of subjects: 314
Study 9383759 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 314
Study 8197772 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Number of subjects: 58
Study 8197772 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous normothermic peritoneal perfusion (CNPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Number of subjects: 58
Study 8197772 — intervention group
Group type: COMPARATOR
Intervention: Control group (gastric surgery without perfusion)
Number of subjects: 58
Study 2839628 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily (n = 16)
Number of subjects: 37
Study 2839628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg twice daily (n = 15)
Number of subjects: 37
Study 2839628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg enalapril and 25 mg hydrochlorothiazide twice daily, n = 6)
Number of subjects: 37
Study 2839628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy after 8 additional weeks
Number of subjects: 37
Study 2839628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy after one year
Number of subjects: 37
Study 2839628 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 37
Study 2232494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of a large inorganic acid load
Number of subjects: 0
Study 4937034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 10% lignocaine
Number of subjects: 10
Study 31870692 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 0
Study 31870692 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 31395122 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 923
Study 31395122 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 923
Study 27806666 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (n=68): face-to-face training session, three phone sessions, and a booklet
Number of subjects: 136
Study 27806666 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=68): routine postpartum care on days 1‐3, 10‐15 and 42‐60
Number of subjects: 136
Study 25593120 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 854
Study 23673908 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/d)
Number of subjects: 40
Study 23673908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21422412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 3449
Study 21422412 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen for 2 years
Number of subjects: 3449
Study 19019444 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 607
Study 19019444 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medicine
Number of subjects: 607
Study 17980734 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 826
Study 15254884 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 86
Study 15254884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialic acid
Number of subjects: 86
Study 15254884 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 86
Study 12830543 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 9663538 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 413
Study 9663538 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 413
Study 7944835 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive drug therapy (12.5 to 25 mg of chlorthalidone for step 1; 25 to 50 mg of atenolol for step 2; or 0.05 to 0.10 mg of reserpine if atenolol was contraindicated)
Number of subjects: 4736
Study 7944835 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4736
Study 3065740 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose continuous chlorambucil (regimen A)
Number of subjects: 279
Study 3065740 — intervention group
Group type: COMPARATOR
Intervention: Intermittent chlorambucil plus prednisone (regimen B)
Number of subjects: 279
Study 30352838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg daily
Number of subjects: 235
Study 30352838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide 200 mg daily
Number of subjects: 235
Study 30352838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tamoxifen and Fenretinide
Number of subjects: 235
Study 30352838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 27054677 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive cycling
Number of subjects: 24
Study 27054677 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling
Number of subjects: 24
Study 27054677 — intervention group
Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 24
Study 25248814 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline IGFBP7 concentrations
Number of subjects: 124
Study 25248814 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP7 concentrations
Number of subjects: 124
Study 25248814 — intervention group
Group type: EXPERIMENTAL
Intervention: More time spent with elevated IGFBP7 concentrations
Number of subjects: 124
Study 22451568 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased viewing time for mammography cases
Number of subjects: 119
Study 22451568 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence in assessment
Number of subjects: 119
Study 22451568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower confidence in assessment
Number of subjects: 119
Study 19883392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Number of subjects: 20
Study 19883392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18084173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait trainer (PBWS), 40 minutes sessions, 5 times a week, for 5 weeks
Number of subjects: 40
Study 18084173 — intervention group
Group type: COMPARATOR
Intervention: Bobath method, 40 minutes sessions, 5 times a week, for 5 weeks
Number of subjects: 40
Study 16118090 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate and vitamin D3
Number of subjects: 26
Study 12173362 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenously) during normoglycemia
Number of subjects: 12
Study 12173362 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenously) during hyperglycemia
Number of subjects: 12
Study 12173362 — intervention group
Group type: COMPARATOR
Intervention: Placebo during normoglycemia
Number of subjects: 12
Study 12173362 — intervention group
Group type: COMPARATOR
Intervention: Placebo during hyperglycemia
Number of subjects: 12
Study 10592403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentian violet
Number of subjects: 21
Study 10592403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid
Number of subjects: 21
Study 10592403 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquor carbonis detergens (tar preparation)
Number of subjects: 21
Study 8696696 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 38
Study 8696696 — intervention group
Group type: COMPARATOR
Intervention: Spiral computed tomography (SCT)
Number of subjects: 38
Study 8696696 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 38
Study 8696696 — intervention group
Group type: COMPARATOR
Intervention: Examination under anaesthesia (EUA)
Number of subjects: 38
Study 1656738 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once on day 1 followed by 250 mg once daily for 4 days
Number of subjects: 242
Study 1656738 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 250 mg every 6 hours for 10 days
Number of subjects: 242
Study 1656738 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 242
Study 1656738 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 242
Study 6311790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 87
Study 6311790 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus cefotaxime
Number of subjects: 87
Study 29974299 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 190
Study 29974299 — intervention group
Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 190
Study 27067478 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (2.5 mg three times per day)
Number of subjects: 237
Study 25240461 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs-containing fish oil (average DHA and EPA doses of 72.9 and 117.1 mg/kg b.w./day) for 12 months
Number of subjects: 24
Study 25240461 — intervention group
Group type: COMPARATOR
Intervention: Untreated RTT group (Control)
Number of subjects: 24
Study 23133592 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake of 480 mg/day
Number of subjects: 26
Study 23133592 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/day
Number of subjects: 26
Study 23133592 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant women (n=21)
Number of subjects: 26
Study 20212029 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care involving physicians and pharmacists
Number of subjects: 225
Study 20212029 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 225
Study 20212029 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 225
Study 17392142 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nutritional intervention and health education
Number of subjects: 0
Study 17392142 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple health education
Number of subjects: 0
Study 17392142 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple nutritional intervention
Number of subjects: 0
Study 17392142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 15734767 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2159
Study 15734767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2159
Study 12488154 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive sentinel lymph node (SLN) biopsy
Number of subjects: 1183
Study 12488154 — intervention group
Group type: COMPARATOR
Intervention: Negative sentinel lymph node (SLN) biopsy
Number of subjects: 1183
Study 10221638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (n = 65)
Number of subjects: 131
Study 10221638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 131
Study 8556698 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone and insulin-like growth factor 1 treatment
Number of subjects: 0
Study 8556698 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Number of subjects: 0
Study 2141494 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 72
Study 2141494 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 72
Study 2141494 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) and Medroxyprogesterone acetate (MPA)
Number of subjects: 72
Study 733601 — intervention group
Group type: EXPERIMENTAL
Intervention: One fraction of 2100-2250 R
Number of subjects: 368
Study 733601 — intervention group
Group type: EXPERIMENTAL
Intervention: Four fractions of 1000-4000 R during 4 days
Number of subjects: 368
Study 733601 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight fractions of 600-4800 R during 9 days
Number of subjects: 368
Study 30398382 — intervention group
Group type: EXPERIMENTAL
Intervention: No drain after RARP (SG)
Number of subjects: 112
Study 31651365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use among pregnant women
Number of subjects: 718
Study 31651365 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy
Number of subjects: 718
Study 31651365 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortion history
Number of subjects: 718
Study 31651365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre pregnancy alcohol use
Number of subjects: 718
Study 31651365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental distress
Number of subjects: 718
Study 29056418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (25 μg kg−1)
Number of subjects: 6
Study 29056418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (25 μg kg−1) with MK‐467 (600 μg kg−1)
Number of subjects: 6
Study 26037292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose before PCI
Number of subjects: 213
Study 26037292 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose at the time of PCI
Number of subjects: 213
Study 26037292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 213
Study 26037292 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 213
Study 24209894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Number of subjects: 50
Study 24209894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20881877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=97)
Number of subjects: 185
Study 20881877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 185
Study 20881877 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care, n=88)
Number of subjects: 185
Study 19921566 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision (LTME)
Number of subjects: 198
Study 17682674 — intervention group
Group type: EXPERIMENTAL
Intervention: Token test (Orgass version, 1976)
Number of subjects: 200
Study 15365929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine/1.5 microg/kg of fentanyl with 5 microg/mL of epinephrine (group IPBF)
Number of subjects: 60
Study 15365929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 5 microg/mL of epinephrine (group IPB)
Number of subjects: 60
Study 15365929 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (group IPS)
Number of subjects: 60
Study 15365929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (group IVF)
Number of subjects: 60
Study 15365929 — intervention group
Group type: COMPARATOR
Intervention: Interpleural saline (group IPS)
Number of subjects: 60
Study 11830753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (Pletal®)
Number of subjects: 8
Study 9757963 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 0
Study 8983590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluoroscopic current (0.5 mA)
Number of subjects: 0
Study 8983590 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopic current (1.5 mA)
Number of subjects: 0
Study 2135682 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 12
Study 2135682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6453849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate in aqueous-alcohol vehicle
Number of subjects: 29
Study 6453849 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 29
Study 6453849 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 29
Study 31282363 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 647
Study 31282363 — intervention group
Group type: COMPARATOR
Intervention: Eye drops
Number of subjects: 647
Study 28091776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal masks
Number of subjects: 72
Study 28091776 — intervention group
Group type: COMPARATOR
Intervention: Binasal prongs
Number of subjects: 72
Study 25885964 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA (less invasive surfactant administration) group, n=47
Number of subjects: 90
Study 25885964 — intervention group
Group type: COMPARATOR
Intervention: Intubation group, n=43
Number of subjects: 90
Study 25885964 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA group, n=47
Number of subjects: 90
Study 24497658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia and Pain (CBT-PI)
Number of subjects: 367
Study 24497658 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Pain (CBT-P)
Number of subjects: 367
Study 24497658 — intervention group
Group type: COMPARATOR
Intervention: Education-Only Control (EOC)
Number of subjects: 367
Study 21098740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone induction therapy
Number of subjects: 0
Study 21098740 — intervention group
Group type: COMPARATOR
Intervention: Vincristine-adriamycin-dexamethasone
Number of subjects: 0
Study 19179299 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (oral suspension, 2 mg/kg, max 80 mg)
Number of subjects: 26
Study 17331241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 115
Study 17331241 — intervention group
Group type: COMPARATOR
Intervention: Land exercises
Number of subjects: 115
Study 17331241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hydrotherapy and Land exercises)
Number of subjects: 115
Study 15390214 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 (20 microg)
Number of subjects: 20
Study 15390214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11351143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg o.a.d.
Number of subjects: 277